Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients (12-24 years) treated with the minimal invasive Nuss procedure. The study is designed as a single center, prospective, unblinded, randomized clinical trial.
Rationale: The minimal invasive Nuss procedure is currently considered the treatment of choice for pectus excavatum. This procedure is usually associated with severe postoperative pain as great forces are employed on the thoracic cage to correct the sternal depression. Pain is the main limiting factor for early discharge. Epidural analgesia is currently considered gold standard for postoperative pain treatment. Alternative pain management strategies (e.g., patient-controlled analgesia and paravertebral nerve block) have also been described but fail in accomplishing adequate prolonged post-operative pain management. Alternatively, continuous use of opioids comes with side-effects like severe nausea, urinary retention and obstipation. Intercostal nerve cryoablation seems a promising novel technique for postoperative analgesia. Prior studies comparing intercostal cryoablation to other pain treatment modalities after pectus excavatum repair through the minimal invasive Nuss procedure report promising results, but pose significant limitations (e.g., small sample size, retrospective nature with non-matched patient groups or considerable confounders). Objective: Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients treated with the minimal invasive Nuss procedure. Study design: The study protocol is designed for a single center, prospective, unblinded, randomized clinical trial. Study population \& intervention: Intercostal nerve cryoablation will be compared to thoracic epidural analgesia in young pectus excavatum patients (i.e., 12-24 years of age) treated with the minimal invasive Nuss procedure. Block randomization, including stratification based on age (12-16 years and 17-24 years) and sex, with an allocation ratio of 1:1 will be performed. Main study parameters/endpoints: Postoperative length of hospital stay will be recorded as the primary endpoint. Secondary outcomes include: 1) pain intensity; 2) operative time; 3) opioid usage; 4) complications, including neuropathic pain; 5) creatine kinase activity; 6)intensive care unit admissions; 7) readmissions; 8) postoperative mobility; 9) health related quality of Life; 10) days to return to work/school; 11) number of postoperative outpatient visits and 12) hospital costs. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks for study participants are negligible as the cryoablation technique has already been effectively used in the Nuss procedure without any serious side effects. Also, participants will be monitored daily by nursing staff and surgeons while admitted to the hospital. Burden associated with participation in the current study consists of completion of several questionnaires preoperatively and postoperatively.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
50
Intercostal nerve cryoablation is applied during Nuss procedure.
Thoracic epidural is placed prior to Nuss procedure
Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
Zuyderland Medical Center
Heerlen, Limburg, Netherlands
RECRUITINGLength of hospital stay
Number of days of hospital admittance after the Nuss procedure.
Time frame: Hospitalization period, average of 5 days
Pain intensity
Pain intensity at rest and during mobilization. Pain scores will be rated on the numeric rating scale (NRS, 1-10)
Time frame: Preoperative care unit before surgery, in the morning on postoperative day 1 and 2, and 7 days, 14 days, 3 months and 6 months post operation
Operative time
Operative time in minutes. Duration of cryoablation will be assessed separately. Operative time will not include the time needed for the placement of the thoracic epidural as placement will be performed in the preoperative care unit.
Time frame: During Nuss procedure
Opioid usage
A) Intraoperative administered opioids; B) Opioid usage during postoperative day 0, 1 and 2 at the recovery unit and surgical ward; C) Opioid usage within the first 2 weeks after surgery. Opioid usage will be converted to oral morphine milligram equivalents (MME).
Time frame: postoperative day 1 and 2, and first 2 weeks after surgery
Complications
Complications graded according to the Clavien-Dindo classification. The most common procedure- and analgesia-related complications are defined in Supplementary Materials Table 1-2 for transparency, including neuropathic pain. Occurrence of neuropathic pain will be actively monitored during the hospitalization period, and during all follow-up appointments.
Time frame: 6 months postoperative
Creatine kinase (CK) activity
CK levels will be assessed prior to the surgical procedure (i.e., baseline measurement during routine blood evaluation on the day of surgery) and on postoperative day 1. CK levels will be denoted in U/L.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Opioids
Time frame: Preoperative and day 1 postoperative
Intensive care unit admission
Intensive care unit admission due to the occurrence of perioperative complications in absolute numbers
Time frame: Hospitalization period, average of 5 days
Length of intensive care unit admission
Length of admission due to the occurrence of perioperative complications in absolute numbers.
Time frame: Hospitalization period, average of 5 days
Number of readmissions
Number of readmissions denoted as absolute numbers.
Time frame: 6 months postoperative
Length of readmissions
length of readmissions denoted as absolute numbers.
Time frame: 6 months postoperative
Degree of mobility
Degree of mobility measured on a 4-point scale (i.e., 1. on the bed, 2. to the chair, 3. to the toilet, 4. outside the patient's hospital room) during postoperative day 1 and 2.
Time frame: Postoperative day 1 and 2
HRQOL - PEEQ
HRQOL, measured by the Dutch version of the pectus evaluation questionnaire (PEEQ). The PEEQ is a validated disease specific questionnaire evaluating the quality of life in pectus excavatum patients (37,38).
Time frame: Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
HRQOL - SF-36
HRQOL, measured by the Dutch version of the short form health survey (SF-36)(37-40). The SF-36 is a generic questionnaire that taps health in eight dimensions (39).
Time frame: Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
HRQOL - EQ-5D-5L
HRQOL, measured by the Dutch version of the EuroQol 5 dimensions 5 levels (EQ-5D-5L) (37-40). For the EQ-5D-5L, participants will rate their health in 5 dimensions on 5 levels and will give an overall score of their health on a visual analogue scale (VAS) (40).
Time frame: Before surgery as a baseline measurement, and at 2 weeks, 3 months and 6 months after the surgical procedure
Days to return to work/school
Days to return to work/school, reported as days between discharge from hospital and return to work or school.
Time frame: 6 months postoperative
Postoperative visits
Number of postoperative outpatient visits and telephone appointments denoted as absolute numbers in the first 6 months after the surgical procedure.
Time frame: 6 months postoperative
Hospital costs
Hospital costs, reported as hospital costs during initial hospitalization (e.g., medication, patient care supply, surgical equipment), and hospital costs after discharge until 6 months follow-up (e.g., medications, outpatient visits, (opioid related) readmissions).
Time frame: 6 months postoperative